Author: Mitchell Gaydash
31 Mar IIVS Posters – SOT 2023 Annual Meeting
IIVS presented several posters at SOT 2023. This post includes links to the full PDF versions of each poster presented.14 Mar 62nd Annual Meeting of the Society of Toxicology
IIVS is looking forward to exhibiting at the 62nd Annual Meeting of the Society of Toxicology! If attending, please visit us during ToxExpo at booth #834. ...
09 Mar IIVS and Toxys Enter Into Agreement to Offer ToxTracker® for In Vitro Genetic Toxicity Evaluation
The Institute for In Vitro Sciences (IIVS) and Toxys have entered into a license agreement that allows IIVS to offer the ToxTracker® assay. ToxTracker is an innovative in vitroassay allowing identification of the genotoxic and potentially carcinogenic properties of novel and existing drugs, (agro)chemicals, cosmetics...
01 Mar March 2023 Newsletter
IIVS is pleased to share that the PMI In Vitro Alternatives Laboratory in Neuchâtel, Switzerland is now GIVIMP certified. Good In Vitro Method Practices (GIVIMP) is an OECD guidance document that provides a framework for quality standards specific to in vitro laboratory operations....
23 Feb Key Challenges and Recommendations for In Vitro Testing of Tobacco Products for Regulatory Applications: Consideration of Test Materials and Exposure Parameters
The Institute for In Vitro Sciences (IIVS) is sponsoring a series of workshops to identify, discuss and develop recommendations for optimal scientific and technical approaches for conducting in vitro assays, to assess potential toxicity within and across tobacco and various next generation nicotine and tobacco products (NGPs), including heated tobacco products (HTPs) and electronic nicotine delivery systems (ENDS).16 Feb Derivation of a Point of Departure from In Vitro Methods for use in Skin Sensitization Risk Assessment Pt 2
This webinar explores the use of Non-Animal Methodologies to derive a Point of Departure (predicted LLNA EC3) which can be used to evaluate the skin sensitization potency as well as downstream use for risk assessment. Presenters include: Dr. Argel Islas-Robles (Study Director and Toxicologist, IIVS)...
07 Feb Derivation of a Point of Departure from In Vitro Methods for use in Skin Sensitization Risk Assessment Pt 1
This webinar explores the use of Non-Animal Methodologies to derive a Point of Departure (predicted LLNA EC3) which can be used to evaluate the skin sensitization potency as well as downstream use for risk assessment. Presenters include: Dr. Argel Islas-Robles (Study Director and Toxicologist, IIVS)...
03 Feb IIVS Leadership Newsletter
Please join me in congratulating Amanda Ulrey and Kristie Sullivan on their new roles as they work with Hans Rabe, Senior Vice President and Chief Operation Officer, and the rest of the IIVS team to further the IIVS mission of advancing the use and acceptance...